Cyclacel Pharmaceuticals, INC Form 4 insider transactions

A 10% owner and director of Cyclacel Pharmaceuticals, David E. Lazar, sold 6,750 shares of common stock and is no longer subject to Section 16 reporting requirements.

Cyclacel Pharmaceuticals, Inc. issued a press release to address recent stock price volatility, stating no material adverse changes to its operations or financial condition beyond previously disclosed information, including an amendment to its Exchange Agreement with FITTERS Diversified Berhad.

Cyclacel Pharmaceuticals, Inc. has amended its agreement to acquire FITTERS Sdn. Bhd., adding a $1 million cash payment to the consideration and extending the transaction's final closing date to September 30, 2025, citing a decline in Cyclacel's valuation.

Director David Natan receives 700,000 non-qualified stock options in Cyclacel Pharmaceuticals, exercisable immediately, replacing previously reported shares.

Interim CEO David E. Lazar converted Series C and D Preferred Stock into common stock and subsequently sold a large block of common stock in a private transaction.

Director Avraham Ben-Tzvi of Cyclacel Pharmaceuticals, Inc. was granted 700,000 non-qualified stock options on February 26, 2025, exercisable immediately.

David E. Lazar, Interim CEO and 10% Owner of Cyclacel Pharmaceuticals, acquires Series D Convertible Preferred Stock for $2.1 million, convertible into 231 million shares of common stock.

David Natan, a director at Cyclacel Pharmaceuticals, acquired 100,000 shares of restricted stock on January 2, 2025.